NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.03 +0.03 (+0.04%) GOLD FUTURES
2,312.70 +1.70 (+0.07%) DOW
38,153.82 +250.53 (+0.66%) Bitcoin GBP
47,187.08 +1,569.17 (+3.44%)
Mind Medicine (MindMed) Inc. (MNMD)
| Previous close | 9.43 |
| Open | 9.55 |
| Bid | 9.35 x 400 |
| Ask | 9.43 x 100 |
| Day's range | 9.21 - 9.60 |
| 52-week range | 2.41 - 12.22 |
| Volume | |
| Avg. volume | 2,364,827 |
| Market cap | 677.038M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.86 |
Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
NEW YORK, May 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.
Business WireMindMed to Present at Upcoming May Medical Conferences
NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
Business WireMindMed to Present at Upcoming April Medical Conferences
NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
